New issue of Blood Advances out now featuring MRD assessment by flow cytometry in B-ALL made easier, Targeting the lectin pathway in TA-TMA, AI-generated peptides for research and clinical practice, and more. Explore here: ow.ly/6UUP50XWfXv #BloodAdvances #NewIssue
January 13, 2026 at 5:25 PM
New issue of Blood Advances out now featuring MRD assessment by flow cytometry in B-ALL made easier, Targeting the lectin pathway in TA-TMA, AI-generated peptides for research and clinical practice, and more. Explore here: ow.ly/6UUP50XWfXv #BloodAdvances #NewIssue
'Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis' read in Blood Advances: buff.ly/kzxbRAk #bloodadvances
January 7, 2026 at 8:30 PM
'Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis' read in Blood Advances: buff.ly/kzxbRAk #bloodadvances
We're excited to share that Blood Advances has a new Associate Editor, Dr. Steven Lane. He's a clinical hematologist and researcher at Royal Brisbane & Women's Hospital and runs a busy research group at the Queensland Institute of Medical Research. Welcome Dr. Lane! #BloodAdvances
January 7, 2026 at 2:44 PM
We're excited to share that Blood Advances has a new Associate Editor, Dr. Steven Lane. He's a clinical hematologist and researcher at Royal Brisbane & Women's Hospital and runs a busy research group at the Queensland Institute of Medical Research. Welcome Dr. Lane! #BloodAdvances
CD8+ T-cell activation, function, and metabolic reprogramming are suppressed by hypoxia, linked to decreased mTOR activity. Read in Blood Advances: buff.ly/ttZb0at #BloodAdvances #MultipleMyeloma
December 17, 2025 at 4:30 PM
CD8+ T-cell activation, function, and metabolic reprogramming are suppressed by hypoxia, linked to decreased mTOR activity. Read in Blood Advances: buff.ly/ttZb0at #BloodAdvances #MultipleMyeloma
New issue of Blood Advances out now featuring A tale of 2 mice, Reporting infections in cellular therapies, Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations, and more. ashpublications.org/bloodadvance... #BloodAdvances
December 10, 2025 at 4:26 PM
New issue of Blood Advances out now featuring A tale of 2 mice, Reporting infections in cellular therapies, Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations, and more. ashpublications.org/bloodadvance... #BloodAdvances
Welcome to #ASH25! We have a Special Annual Meeting Edition of Blood Advances. Be sure to pick up your free copy this weekend at the ASH Booth (1101) or throughout the convention center. #BloodAdvances #AnnualMeeting #Hemesky
December 5, 2025 at 3:30 PM
Welcome to #ASH25! We have a Special Annual Meeting Edition of Blood Advances. Be sure to pick up your free copy this weekend at the ASH Booth (1101) or throughout the convention center. #BloodAdvances #AnnualMeeting #Hemesky
Explore the new issue of Blood Advances, featuring FcR γ-chain and platelet hyperactivity, Deferral of immunosuppression in acquired hemophilia, Diagnosis of von Willebrand disease and more. ashpublications.org/bloodadvance... #BloodAdvances #NewIssue #Hemesky
November 26, 2025 at 4:14 PM
Explore the new issue of Blood Advances, featuring FcR γ-chain and platelet hyperactivity, Deferral of immunosuppression in acquired hemophilia, Diagnosis of von Willebrand disease and more. ashpublications.org/bloodadvance... #BloodAdvances #NewIssue #Hemesky
LEN with DA–EPOCH-R had a complete response rate of 83.6% in patients with DHL and DEL with no unexpected toxicities. Read in Blood Advances: buff.ly/NUvoHSQ #BloodAdvances #Hemesky
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Key PointsLEN with DA–EPOCH-R had a complete response rate of 83.6% in patients with DHL and DEL with no unexpected toxicities.With a median follow-up of 3
buff.ly
November 23, 2025 at 6:15 PM
LEN with DA–EPOCH-R had a complete response rate of 83.6% in patients with DHL and DEL with no unexpected toxicities. Read in Blood Advances: buff.ly/NUvoHSQ #BloodAdvances #Hemesky
Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/…
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
https://ashpublications.org/bloodadvances/…
October 29, 2025 at 11:47 AM
Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/…
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19)
👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 m#mdsds
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML
October 29, 2025 at 11:24 AM
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOSOS 24 mo.#cross-trialal comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo#leusms#AMLML
#PublicaSalutIB 💉🧴 Hematologia de Son Espases ha participat en la publicació d'un estudi on s'analitza l'ús del
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
October 13, 2025 at 3:01 PM
#PublicaSalutIB 💉🧴 Hematologia de Son Espases ha participat en la publicació d'un estudi on s'analitza l'ús del
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
#PublicaSalutIB 💉🧴 Hematología de Son Espases ha participado en la publicación de un estudio sobre el uso del tafasitamab más lenalidomida como terapia de rescate en el linfoma difuso de células B grandes https://www.infosalut.com/es/17924 https://doi.org/10.1182/bloodadvances.2025016661 @SonEspases
October 6, 2025 at 4:01 PM
#PublicaSalutIB 💉🧴 Hematología de Son Espases ha participado en la publicación de un estudio sobre el uso del tafasitamab más lenalidomida como terapia de rescate en el linfoma difuso de células B grandes https://www.infosalut.com/es/17924 https://doi.org/10.1182/bloodadvances.2025016661 @SonEspases
#PublicaSalutIB 💉🧴 Hematologia de Son Espases ha participat en la publicació d'un estudi on s'analitza l'ús del
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
October 6, 2025 at 9:01 AM
#PublicaSalutIB 💉🧴 Hematologia de Son Espases ha participat en la publicació d'un estudi on s'analitza l'ús del
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
tafasitamab més lenalidomida com a teràpia de rescat en el limfoma difús de cèl·lules B grans https://www.infosalut.com/17924 https://doi.org/10.1182/bloodadvances.2025016661
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
September 2, 2025 at 12:02 PM
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
August 26, 2025 at 6:02 PM
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
August 26, 2025 at 11:01 AM
#PublicaSalutIB 🦠🔬Aina Oliver-Caldés de Son Espases i @idisba.bsky.social ha participat en la publicació d'un estudi sobre el tractament prometedor per al mieloma múltiple https://www.infosalut.com/investigacio/estudis-i-projectes/17773 https://doi.org/10.1182/bloodadvances.2024014360
#PublicaSalutIB 🩸💊 Hematologia de Son Espases i Son Llàtzer han participat en un estudi on s'analitza el trasplantament autòleg per a limfoma B gran recaigut/refractari https://www.infosalut.com/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
July 21, 2025 at 3:30 PM
#PublicaSalutIB 🩸💊 Hematologia de Son Espases i Son Llàtzer han participat en un estudi on s'analitza el trasplantament autòleg per a limfoma B gran recaigut/refractari https://www.infosalut.com/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
#PublicaSalutIB 🩸💊 Hematología de Son Espases y Son Llàtzer han participado en un estudio donde se analiza el trasplante autólogo para linfoma B gran recaído/refractario https://www.infosalut.com/es/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
July 14, 2025 at 6:01 PM
#PublicaSalutIB 🩸💊 Hematología de Son Espases y Son Llàtzer han participado en un estudio donde se analiza el trasplante autólogo para linfoma B gran recaído/refractario https://www.infosalut.com/es/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
#PublicaSalutIB 🩸💊 Hematologia de Son Espases i Son Llàtzer han participat en un estudi on s'analitza el trasplantament autòleg per a limfoma B gran recaigut/refractari https://www.infosalut.com/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
July 14, 2025 at 11:01 AM
#PublicaSalutIB 🩸💊 Hematologia de Son Espases i Son Llàtzer han participat en un estudi on s'analitza el trasplantament autòleg per a limfoma B gran recaigut/refractari https://www.infosalut.com/investigacio/estudis-i-projectes/17643 https://doi.org/10.1182/bloodadvances.2024015415
Thank you to Blood Cancers Today for allowing me to talk about our newly published study in @BloodAdvances on the increased risk of #ALCL Breast Implant associated lymphoma in #BRCA 1/2 carriers. #MSKCancerCenter #ColumbiaMSPH. www.bloodcancerstoday.com/post/brca-mu...
BRCA Mutations Linked to Higher Risk of Rare T-Cell Lymphoma for Women With Textured Breast Implants | Blood Cancers Today
Paola Ghione, MD, MSEpi, discusses recent findings on breast implant-associated anaplastic large cell lymphoma and how this rare T-cell lymphoma is typically managed.
www.bloodcancerstoday.com
June 30, 2025 at 8:50 PM
Thank you to Blood Cancers Today for allowing me to talk about our newly published study in @BloodAdvances on the increased risk of #ALCL Breast Implant associated lymphoma in #BRCA 1/2 carriers. #MSKCancerCenter #ColumbiaMSPH. www.bloodcancerstoday.com/post/brca-mu...
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation url:https://ashpublications.org/bloodadvances/article/9/10/2553/535454/Intermediate-dose-posttransplantation
May 27, 2025 at 8:17 PM
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation url:https://ashpublications.org/bloodadvances/article/9/10/2553/535454/Intermediate-dose-posttransplantation
Breaking the cycle: PRMTs and secondary HLH relief url:https://ashpublications.org/bloodadvances/article/9/10/2436/537247/Breaking-the-cycle-PRMTs-and-secondary-HLH-relief
May 17, 2025 at 1:39 PM
Breaking the cycle: PRMTs and secondary HLH relief url:https://ashpublications.org/bloodadvances/article/9/10/2436/537247/Breaking-the-cycle-PRMTs-and-secondary-HLH-relief
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma url:https://ashpublications.org/bloodadvances/article/9/9/2122/535555/Single-cell-dynamics-of-breakthrough-toxicities
May 15, 2025 at 8:03 AM
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma url:https://ashpublications.org/bloodadvances/article/9/9/2122/535555/Single-cell-dynamics-of-breakthrough-toxicities
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy
Blood Adv bloodadvances.2025016346.
doi.org/10.1182/bloo...
Blood Adv bloodadvances.2025016346.
doi.org/10.1182/bloo...
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy
Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lakha Mikkilineni, Sebastian Fernandez-Pol, Darren Salmi, Robert S. Negrin, Parveen Shiraz, Melody Smith, S
doi.org
May 13, 2025 at 10:25 AM
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy
Blood Adv bloodadvances.2025016346.
doi.org/10.1182/bloo...
Blood Adv bloodadvances.2025016346.
doi.org/10.1182/bloo...
#RedBloodCells (RBCs) display mechanically active role in contraction of #BloodClots: Platelet-depleted clots formed in the presence of RBCs exhibited >20% volume shrinkage 10.1182/bloodadvances.2024015533 #Thrombosis #Hemostasis #TranslationalScience
Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage
Key Points. RBCs suspended in platelet-depleted plasma undergo aggregation within a thrombin-induced clot and cause platelet-independent clot shrinkage.RBC
urldefense.com
April 22, 2025 at 10:36 PM
#RedBloodCells (RBCs) display mechanically active role in contraction of #BloodClots: Platelet-depleted clots formed in the presence of RBCs exhibited >20% volume shrinkage 10.1182/bloodadvances.2024015533 #Thrombosis #Hemostasis #TranslationalScience